Oragenics (OGEN) Non Operating Interest Expenses (2010 - 2026)

Oragenics (OGEN) has reported Non Operating Interest Expenses for 17 consecutive years, with $414.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 99.93% year-over-year to $414.0; the trailing twelve-month figure through Jun 2026 stood at $18634.0 (down 97.65% YoY), and the FY2025 full-year result was $785930.0, up 2534.87% from the prior year.
• Non Operating Interest Expenses retreated to $414.0 in Q2 2026 per OGEN's latest filing, from $3727.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $572310.0 in Q2 2025 and bottomed at $414.0 in Q2 2026.
• Historically, Non Operating Interest Expenses has averaged $48088.5 across 5 years, with a median of $6426.0 in 2022.
• The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses surged 31642.1% in 2025, then plunged 99.93% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at $5813.0 in 2022, then surged by 110.41% to $12231.0 in 2023, then declined by 10.32% to $10969.0 in 2024, then sank by 32.04% to $7454.0 in 2025, then plunged by 94.45% to $414.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $414.0, $3727.0, and $7454.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.